Advances in nanomaterials for photodynamic therapy applications: Status and challenges
Source abstract
Abstract
Photodynamic therapy (PDT), as a non-invasive therapeutic modality that is alternative to radiotherapy and chemotherapy, is extensively investigated for cancer treatments. Although conventional organic photosensitizers (PSs) are still widely used and have achieved great progresses in PDT, the disadvantages such as hydrophobicity, poor stability within PDT environment and low cell/tissue specificity largely limit their clinical applications. Consequently, nano-agents with promising physicochemical and optical properties have emerged as an attractive alternative to overcome these drawbacks of traditional PSs. Herein, the up-to-date advances in the fabrication and fascinating applications of various nanomaterials in PDT have been summarized, including various types of nanoparticles, carbon-based nanomaterials, and two-dimensional nanomaterials, etc. In addition, the current challenges for the clinical use of PDT, and the corresponding strategies to address these issues, as well as future perspectives on further improvement of PDT have also been discussed.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence Properties of Advanced Materials · Luminescence and Fluorescent Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. World Health Organization
2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA10.3322/caac.21492 ↗
3. An updated overview on the development of new photosensitizers for anticancer photodynamic therapy10.1016/j.apsb.2017.09.003 ↗
4. Nanoparticles in photodynamic therapy10.1021/cr5004198 ↗
5. Photodynamic therapy: past, present and future10.1002/tcr.201600121 ↗
6. Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma10.1158/2326-6066.CIR-17-0235 ↗
7. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma10.1038/leu.2017.322 ↗
8. Combined radiotherapy and anti–PD-L1 antibody synergistically enhances antitumor effect in non–small cell lung cancer10.1016/j.jtho.2017.04.014 ↗
9. Nanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment10.1002/ijc.31717 ↗
10. Diaz · 2003
11. Side effects related to systemic cancer treatment: are we changing the Promethean experience with molecularly targeted therapies?10.3747/co.v15i4.362 ↗
12. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial10.1016/S1470-2045(16)30364-3 ↗
13. Photodynamic therapy10.1093/jnci/90.12.889 ↗
14. Targeted and effective photodynamic therapy for cancer using functionalized nanomaterials10.1016/j.apsb.2016.01.007 ↗
15. Photodynamic therapy for cancer10.1038/nrc1071 ↗
16. Laser and non-laser light sources for photodynamic therapy10.1007/s101030200027 ↗
17. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light10.1093/jnci/55.1.115 ↗
18. An overview on preclinical and clinical experiences with photodynamic therapy for bladder cancer
19. Photodynamic therapy in the management of lesions of the head and neck10.1016/j.bjoms.2012.11.011 ↗
20. Photodynamic therapy in dermatology: current treatments and implications
21. Targeted photodynamic therapy10.1002/lsm.20345 ↗
22. Role of various nanoparticles in photodynamic therapy and detection methods of singlet oxygen10.1016/j.pdpdt.2019.03.016 ↗
23. Some relationships of porphyrins, X-rays and tumors
24. Photodynamic therapy in oncology10.1634/theoncologist.11-9-1034 ↗
25. Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (photofrin), 2-[1-Hexyloxyethyl]-2-devinyl pyropheophorbide-a (photochlor) and 5-ALA-induced protoporphyrin IX10.1002/lsm.20340 ↗
26. Photodynamic therapeutics: basic principles and clinical applications10.1016/S1359-6446(99)01412-9 ↗
27. Supramolecular photosensitizers rejuvenate photodynamic therapy10.1039/C7CS00594F ↗
28. Near‐Infrared‐II molecular dyes for cancer imaging and surgery
29. Near-infrared fluorophores for biomedical imaging10.1038/s41551-016-0010 ↗
30. Effects of photodynamic therapy mediated by nanoemulsion containing chloro-aluminum phthalocyanine: a histologic and immunohistochemical study in human gingiva10.1016/j.pdpdt.2015.10.009 ↗
31. Aluminium-phthalocyanine chloride nanoemulsions for anticancer photodynamic therapy: development and in vitro activity against monolayers and spheroids of human mammary adenocarcinoma MCF-7 cells10.1186/s12951-015-0095-3 ↗
32. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical–translational studies10.1016/j.taap.2007.01.025 ↗
33. Preclinical evaluation of zinc phthalocyanine tetrasulfonate-based PDT10.1117/12.588378 ↗
34. Photodynamic therapy: the development of new photosensitisers, anticancer
35. Photodynamic therapy of head and neck cancers10.1007/978-1-60761-697-9_18 ↗
36. Porphycene-a novel porphin isomer10.1002/anie.198602571 ↗
37. Tetra-n-propylporphycene as a tumour localizer: pharmacokinetic and phototherapeutic studies in mice10.1016/0304-3835(89)90100-6 ↗
38. Hypericin and pseudohypericin in some Hypericum species10.1016/S0305-1978(00)00032-6 ↗
39. Hypericin - the facts about a controversial agent10.2174/1381612053382287 ↗
40. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin10.1007/s00262-011-1184-2 ↗
41. Methylene blue in photodynamic therapy: from basic mechanisms to clinical applications10.1016/S1572-1000(05)00097-9 ↗
42. Using chitosan gels as a toluidine blue O delivery system for photodynamic therapy of buccal cancer: in vitro and in vivo studies10.1016/j.pdpdt.2014.11.003 ↗
43. An investigation into the potential of phenothiazinium-based photo-sensitisers to act as PDT agents10.1016/S1572-1000(04)00046-8 ↗
44. Comparison of the cytotoxic effects of merocyanine-540 on leukemic cells and normal human bone marrow
45. A comparative study of the photosensitizing characteristics of some cyanine dyes10.1016/S1011-1344(00)00021-X ↗
46. Rose bengal acetate PhotoDynamic therapy (RBAc-PDT) induces exposure and release of damage-associated molecular patterns (DAMPs) in human HeLa cells10.1371/journal.pone.0105778 ↗
47. Photodynamic therapy: porphyrins and phthalocyanines as photosensitizers10.1071/CH08145 ↗
48. Photosensitizers for photodynamic therapy10.1002/adhm.201900132 ↗
49. Motexafin gadolinium: a novel redox active drug for cancer therapy10.1016/j.semcancer.2006.09.002 ↗
50. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer, photochem10.1111/j.1751-1097.1996.tb09647.x ↗
51. 5-Aminolaevulinic acid peptide prodrugs enhance photosensitization for photodynamic therapy10.1158/1535-7163.MCT-08-0092 ↗
52. Synthesis and in vitro photodynamic activity of novel galactose-containing phthalocyanines10.1016/j.tetlet.2004.12.137 ↗
53. New photodynamic therapy with next-generation photosensitizers10.21037/atm.2017.03.59 ↗
54. Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy10.2174/092986707780830970 ↗
55. Reactive oxygen species (ROS)-Based nanomedicine10.1021/acs.chemrev.8b00626 ↗
56. Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer10.1016/j.lungcan.2017.09.002 ↗
57. EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles10.2147/IJN.S148305 ↗
58. Nanomaterials and singlet oxygen photosensitizers: potential applications in photodynamic therapy10.1039/b311429e ↗
59. Thiolate ligands for synthesis of water-soluble gold clusters10.1021/ja046114i ↗
60. Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine10.1021/ar7002804 ↗
61. Gold nanoparticles in delivery applications10.1016/j.addr.2008.03.016 ↗
62. First demonstration of gold nanorods-mediated photodynamic therapeutic destruction of tumors via near infra-red light activation10.1002/smll.201302719 ↗
63. Designing multi-branched gold nanoechinus for NIR light activated dual modal photodynamic and photothermal therapy in the second biological window10.1002/adma.201400703 ↗
64. Gold nanoshells-mediated bimodal photodynamic and photothermal cancer treatment using ultra-low doses of near infra-red light10.1016/j.biomaterials.2014.03.065 ↗
65. Absorption-dependent generation of singlet oxygen from gold bipyramids excited under low power density10.1039/C5RA15362J ↗
66. Metal nanoparticles sensitize the formation of singlet oxygen10.1002/anie.201105236 ↗
67. Light-induced generation of singlet oxygen by naked gold nanoparticles and its implications to cancer cell phototherapy10.1002/smll.201301365 ↗
68. Two-photon induced photoluminescence and singlet oxygen generation from aggregated gold nanoparticles10.1021/am4007403 ↗
69. Gold nanoparticles in cancer treatment10.1021/acs.molpharmaceut.8b00810 ↗
70. Recent progress in metal-based nanoparticles mediated photodynamic therapy10.3390/molecules23071704 ↗
71. Morphology dependent photosensitization and formation of singlet oxygen (1Δg) by gold and silver nanoparticles and its application in cancer treatment10.1039/c3tb20806k ↗
72. Recent advances in metal nanoparticles in cancer therapy10.1080/1061186X.2017.1400553 ↗
73. Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria10.1038/cddis.2013.314 ↗
74. The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties10.1562/0031-8655(2003)0780587TEOMIS2.0.CO2 ↗
75. Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy10.1021/nn4011686 ↗
76. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer10.1021/nl0714637 ↗
77. Designed fabrication of silica-based nanostructured particle systems for nanomedicine applications10.1002/adfm.200800731 ↗
78. Silica-based nanoparticles for photodynamic therapy applications10.1039/c0nr00096e ↗
79. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape10.1016/j.biomaterials.2012.07.025 ↗
80. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT10.1016/j.ijpharm.2011.11.045 ↗
81. Chlorin e6 conjugated silica nanoparticles for targeted and effective photodynamic therapy10.1016/j.pdpdt.2017.06.001 ↗
82. A dual model imaging theragnostic system based on mesoporous silica nanoparticles for enhanced cancer phototherapy10.1002/adhm.201900840 ↗
83. Sequential protein-responsive nanophotosensitizer complex for enhancing tumor-specific therapy10.1021/acsnano.9b01100 ↗
84. A pH-responsive stellate mesoporous silica based nanophotosensitizer for: in vivo cancer diagnosis and targeted photodynamic therapy10.1039/C8BM00386F ↗
85. Generation of singlet oxygen at room temperature mediated by energy transfer from photoexcited porous Si10.1103/PhysRevB.70.085311 ↗
86. Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells10.1021/nn1035262 ↗
87. Two-photon fluorescence imaging and therapy of cancer cells with anisotropic gold-nanoparticle-supported porous silicon nanostructures
88. Ethylene glycol-mediated synthetic route for production of luminescent silicon nanorod as photodynamic therapy agent10.1007/s40843-017-9101-5 ↗
89. Quantifying RNA−Peptide interaction by single-quantum dot-based nanosensor: an approach for drug screening10.1021/ac071225w ↗
90. Quantum dot-based energy transfer: perspectives and potential for applications in photodynamic therapy10.1562/2005-05-11-IR-525 ↗
91. Two-photon excitation of quantum-dot-based fluorescence resonance energy transfer and its applications10.1002/adma.200602036 ↗
92. Semiconductor quantum dots as two-photon sensitizers10.1021/ja0781285 ↗
93. Fluorescence resonance energy transfer between a quantum dot donor and a dye acceptor attached to DNA10.1039/b508911e ↗
94. Biocompatible CdSe quantum dot-based photosensitizer under two-photon excitation for photodynamic therapy10.1039/c0jm03229h ↗
95. Self-assembled nanoscale biosensors based on quantum dot FRET donors10.1038/nmat961 ↗
96. Singlet oxygen generation from water-soluble quantum dot-organic dye nanocomposites10.1021/ja057959c ↗
97. Chlorin e6–ZnSe/ZnS quantum dots based system as reagent for photodynamic therapy10.1088/0957-4484/26/5/055102 ↗
98. Rational engineering of semiconductor QDs enabling remarkable 1O2 production for tumor-targeted photodynamic therapy10.1016/j.biomaterials.2017.09.026 ↗
99. Ag2S quantum dot: a bright and biocompatible fluorescent nanoprobe in the second near-infrared window10.1021/nn301218z ↗
100. Bioluminescence resonance energy transfer using luciferase-immobilized quantum dots for self-illuminated photodynamic therapy10.1016/j.biomaterials.2012.08.044 ↗